Syncom Formulations (India) Limited (BOM: 524470)

Market Cap	19.54B
Revenue (ttm)	3.29B
Net Income (ttm)	331.45M
Shares Out	940.00M
EPS (ttm)	0.36
PE Ratio	57.92
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	602,318
Open	20.38
Previous Close	20.26
Day's Range	20.35 - 21.00
52-Week Range	9.80 - 27.94
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Syncom Formulations (India)

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It provides life care, evolve, and right nutrition products under the Cratus brand. In addition, the company engages in the trading of comm...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 998
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524470

Financial Performance

In 2023, Syncom Formulations (India)'s revenue was 2.63 billion, an increase of 17.45% compared to the previous year's 2.24 billion. Earnings were 253.14 million, an increase of 26.13%.